Ionis Pharmaceuticals to Present New Data on Donidalorsen for Hereditary Angioedema at AAAAI/WAO Joint Congress

Ionis Pharmaceuticals, Inc.  announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three yea...

February 21, 2025 | Friday | News
European Commission Grants Conditional Marketing Authorization for Gilead’s Seladelpar in Primary Biliary Cholangitis

Gilead Sciences, Inc. announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of prima...

February 21, 2025 | Friday | News
Bristol Myers Squibb Announces Positive Final Overall Survival Data for Opdivo® in Resectable NSCLC

Bristol Myers Squibb announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo (ni...

February 21, 2025 | Friday | News
Phanes Therapeutics Doses First Patient in Clinical Trial of Peluntamig (PT217) for Advanced Cancers

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, announced that the f...

February 20, 2025 | Thursday | News
Spinal Cord Injury (SCI) Cases Expected to Rise by 2034, Highlighting the Need for Improved Treatments and Support

Spinal cord injury (SCI) is a sudden disruption of the spinal cord's neural tissue within the spinal canal, caused by trauma, disease, or degeneration. Thi...

February 20, 2025 | Thursday | News
Merilog Receives FDA Approval as the First Rapid-Acting Insulin Biosimilar

The U.S. Food and Drug Administration (FDA) approved Merilog (insulin aspart szij) as a Novolog biosimilar to (insulin aspart) to improve glycemi...

February 20, 2025 | Thursday | News
Ultragenyx Announces FDA Acceptance of BLA for UX111 Gene Therapy to Treat Sanfilippo Syndrome Type A

Ultragenyx Pharmaceutical Inc. announced the U.S. Food and Drug Administration (FDA or the Agency) has accepted for review the Biologics License Applicatio...

February 19, 2025 | Wednesday | News
Grifols Completes Recruitment for Phase 1/2 Study of Subcutaneous Alpha1-Proteinase Inhibitor for AAT Deficiency

Grifols , a global healthcare company and leading manufacturer of plasma-derived medicines,  announced it has finished recruiting the second cohort of...

February 19, 2025 | Wednesday | News
Biogen and Stoke Therapeutics Collaborate on Zorevunersen for Dravet Syndrome Treatment

Biogen Inc.  and Stoke Therapeutics, Inc. announced a collaboration for the development and commercialization of zorevunersen, a potential f...

February 19, 2025 | Wednesday | News
Sanofi and Regeneron’s Dupixent Gains FDA Priority Review for Bullous Pemphigoid Treatment

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) t...

February 19, 2025 | Wednesday | News
European Commission Grants Conditional Approval for Merck’s WELIREG® (belzutifan) to Treat VHL Disease-Associated Tumors and Advanced RCC

 Merck known as MSD outside of the United States and Canada, announced that the European Commission (EC) has conditionally approved WELIREG® ...

February 19, 2025 | Wednesday | News
3Z Pharmaceuticals Unveils Groundbreaking Study Supporting Amlodipine as a Novel Non-Stimulant ADHD Therapy

3Z Pharmaceuticals announced the publication of a transformative study in Neuropsychopharmacology, highlighting compelling scientific evidence that positio...

February 18, 2025 | Tuesday | News
AltaPointe Health Launches Specialized Program to Support Women Battling Substance Use Disorders

 AltaPointe Health, a leading provider of behavioral health services in Alabama, is making strides in addressing substance use disorders among wo...

February 18, 2025 | Tuesday | News
Rznomics’ RZ-001 Receives Fast Track Designation from FDA for Hepatocellular Carcinoma Treatment

Rznomics announced on the 14th that its anticancer drug, RZ-001, has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for t...

February 18, 2025 | Tuesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close